Montelukast sodium
Leukotriene CysLT1 antagonist and GPR17 antagonist / Potent, selective CysLT1 receptor (leukotriene D4) antagonist (Ki = 0.18 nM).1,2 Displays anti-inflammatory and anti-asthmatic effects. Clinically useful agent for treatment of chronic asthma.3 Attenuates chronic brain injury after focal cerebral ischemia in rodent models.4 Decreases blood brain barrier dysfunction in mouse models.5 Blockade of GPR17 by montelukast elevates neural stem and progenitor proliferation.6
Biochemicals & reagents
151767-02-1
MK-0476
1) Lynch et al. (1999), Characterization of the human cysteinyl leukotriene CysLT1 receptor; Nature, 399 789 2) Jones et al. (1995), Pharmacology of montelukast sodium (Singulair), a potent and selective leukotriene D4 receptor antagonist; Can. J. Physiol. Pharmacol., 73 191 3) Reiss et al. (1998), Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group; Arch. Intern. Med., 158 1213 4) Zhao et al. (2011), Montelukast, a cysteinyl leukotriene receptor-1 antagonist, attenuates chronic brain injury after focal cerebral ischaemia in mice and rats; J. Pharm. Pharmacol., 63 550 5) Lenz et al. (2014), Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction; Neuroscience, 277 859 6) Huber et al. (2011) Inhibition of leukotriene receptors boosts neural progenitor proliferation; Cell Physiol. Biochem., 28 793
-20°C
TARGET: GPCR -- PATHWAY: Lipid signaling; Proliferation -- RESEARCH AREA: Stem cells; Neuroscience -- DISEASE AREA: Neurodegeneration; InflammationIschemia